Advertisement

Journal of Tongji Medical University

, Volume 15, Issue 3, pp 143–146 | Cite as

Correlative study on the expression of p53 and DNA ploidy in acute nonlymphocytic leukemia

  • Lin Feng-ru
  • Yao Er-gu
  • Zuo Lian-fu
  • Xu Shi-rong
  • Ren Jin-hai
  • Liu Su-yun
  • Wei Jun-ping
Article
  • 24 Downloads

Summary

We used the flow cytometric immunoassay to study the correlation between the tumor-suppressor gene product p53 and the DNA ploidy in 30de novo cases of acute nonlymphocytic leukemia (ANLL). The results showed that 15 cases were negative and the other 15 cases were positive expression for p53. As compared with p53 negative (p53) cases, the patients with positive p53 (p53+) had higher percentage of bone marrow blasts and lower peripheral leukocyte and platelet counts, which had no influence on the complete remission rate. Before treatment, DNA diploidy was seen in 18 cases including 12 p53 cases, and DNA aneuploidy in 12 cases including 9 p53+. After therapy, aneuploidy could be transformed into diploidy. Patients with P53+ or having aneuploidy in complete remission were at risk for early relapse. We believe that p53 may be involved in the process of leukemogenesis and progression of ANLL.

Key words

p53 tumor-suppressor gene DNA ploidy flow cytometry acute nonlymphocytic leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Levine A J, Momand J, Finlay C A. The p53 tumor suppressor gene. Nature, 1991, 351: 453.PubMedCrossRefGoogle Scholar
  2. 2.
    Harris C C, Hollstein M. Clinical implication of the p53 tumor-suppressor gene. N Eng J Med, 1993, 329:1318.CrossRefGoogle Scholar
  3. 3.
    Zhang R X, Yao E G. The prognostic significance of flow cytometry DNA measurement in acute leukemia. Chin J Hematol, 1989, 10:415.Google Scholar
  4. 4.
    Zhang R X, Yao E G. Flow cytometry DNA measurement for prediction of effect of therapy in acute leukemia. J Tongji Med Uni, 1990, 10: 181.CrossRefGoogle Scholar
  5. 5.
    Zhang R X, Yao E G. Significance of FCM-DNA measurement in detecting minimal residual disease in leukemia. Chin Med J, 1990, 103: 826.PubMedGoogle Scholar
  6. 6.
    Danova M, Giordano M, Mazzini Get al. Expression of p53 protein during the cell cycles measured by flow cytometry in human leukemia. Leu Res, 1990, 14:417.CrossRefGoogle Scholar
  7. 7.
    Qi F Y, Qing T W, Liu X Yet al. Study on the expression of ras oncogene product p21 and DNA ploidy in oral squamous cell carcinoma. Chin J Phy Med, 1993, 15:24.Google Scholar
  8. 8.
    Smith L J, McCulloch A M, Benchimol S. Expression of the p53 oncogene in acute myeloblastic leukemia. J Exp Med, 1986, 164: 751.PubMedCrossRefGoogle Scholar
  9. 9.
    Langois R G, Bigbee W L, Jensen R H. Measurements of the frequency of human erythrocytes with gene expression loss phenotypes at the glycophorin A locus. Hum Genet, 1986, 74:353.CrossRefGoogle Scholar
  10. 10.
    Bighee W L, Wyrobek A J, Langois R Get al. The effect of chemotherapy on the in vivo frequency of glycophorin A “ null” variant erythrocytes. Mut Res, 1990, 240:165.CrossRefGoogle Scholar

Copyright information

© Springer 1995

Authors and Affiliations

  • Lin Feng-ru
    • 1
  • Yao Er-gu
    • 1
  • Zuo Lian-fu
    • 2
  • Xu Shi-rong
  • Ren Jin-hai
    • 1
  • Liu Su-yun
    • 1
  • Wei Jun-ping
    • 1
  1. 1.Hematology Research Laboratory, Second Affiliated HospitalHebei Medical UniversityShijiazhuang
  2. 2.Cell Analysis Laboratory, Fourth Affiliated HospitalHebei Medical UniversityShijiazhuang

Personalised recommendations